Citadel Advisors’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Citadel Advisors’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,426	Closed	-$446K	–	14998
2021 Q1	$446K	Sell	7,426 -410,462	-98%	-$14.9M	﹤0.01%	9933
2020 Q4	$6.21M	Buy	417,888 +327,572	+363%	+$4.56M	﹤0.01%	3319
2020 Q3	$1.03M	Buy	+90,316	New	+$1.54M	﹤0.01%	5970

Citadel Advisors's PAND Position: Q2 2021 in Review

Citadel Advisors sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 7,426 shares — an estimated $446K sold.

Citadel Advisors first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $6.21M in Q4 2020. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

Citadel Advisors reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 7,426 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $446K.
Citadel Advisors first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
Citadel Advisors's Pandion Therapeutics Inc. Common Stock position peaked at $6.21M in Q4 2020.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.